Navigation Links
Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
Date:5/16/2012

ational compound.  Afatinib is not approved by the FDA; its safety and efficacy have not been established. 

Afatinib is an investigational oral, once-daily irreversible ErbB Family Blocker that specifically inhibits epidermal growth factor receptor (EGFR or ErbB1), human epidermal receptor 2 (HER2 or ErbB2), ErbB3 and ErbB4.  It is currently in phase III clinical development in NSCLC, head and neck and breast cancer. 

About the Afatinib Clinical Trial Program in Advanced NSCLCThe LUX-Lung studies evaluate the use of afatinib in various settings of advanced NSCLC, including in patients harboring EGFR mutations and those with recurrent disease.  These trials include:

  • LUX-Lung 1, a Phase IIb/III trial investigating afatinib plus best supportive care (BSC) versus placebo plus BSC in NSCLC patients who were previously treated with first-line chemotherapy and the reversible EGFR TKIs erlotinib or gefitinib.
  • LUX-Lung 2, a Phase II trial evaluating afatinib in NSCLC patients with EGFR mutations (EGFR M+), either treatment-naive or after one line of treatment with chemotherapy.
  • LUX-Lung 3, a Phase III trial investigating afatinib as a first-line treatment in patients with advanced NSCLC with EGFR mutations. 
  • LUX-Lung 4, a Phase I/II trial of afatinib in NSCLC patients who have progressed after conventional EGFR-TKI treatment. 
  • LUX-Lung 5, a global Phase III trial in patients previously treated with erlotinib or gefitinib. This is the first randomized Phase III trial investigating whether patients who initially benefit from treatment with afatinib alone may further benefit from afatinib beyond progression when given in combination with chemotherapy.
  • LUX-Lung 6, a Phase III trial investigating the efficacy and safety of afatinib compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations.
  • LUX-Lung 7, a Phase IIb trial e
    '/>"/>

    • SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
    2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
    3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
    4. Boehringer Ingelheim Unveils Diabetes Pipeline
    5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
    6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
    7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
    8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
    9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
    10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
    11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/24/2013)... CHESTERBROOK, Pa. , May 24, 2013  Auxilium ... that executive management will participate in the Deutsche Bank ... the Westin Boston Waterfront Hotel.  Mr. Adrian ... scheduled to present an overview of the Company and ... May 29, 2013.   (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
    (Date:5/24/2013)... BEIJING , May 24, 2013  Sinovac ... leading provider of biopharmaceutical products in ... main operating subsidiary company of Sinovac, obtained the ... (GMP Certificate) from the China State and Food ... district bulk production plants, and its Changping filing ...
    (Date:5/24/2013)... England and BOSTON , May 24, ... discovery and development company, is pleased to announce that it has ... to augment the Company,s business development capabilities in Japan ... more than 15 years of experience in business development, licensing and ... Sciences, Inc., Roche Pharma ( Japan ), Nippon Roche ...
    Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2
    ... MERCER ISLAND, Wash., Dec. 22, 2010 Renal Advantage and ... the third largest provider of dialysis services in the U.S., ... – terms of which were not disclosed – was completed ... serving more than 19,000 patients in 260 locations in 32 ...
    ... AstraZeneca (NYSE: AZN ... will discontinue the development of CERTRIAD™ (rosuvastatin calcium and fenofibric ... dyslipidemia. This means the co-development and license agreement with Abbott ... Complete Response Letter (CRL) for the CERTRIAD New Drug Application ...
    Cached Medicine Technology:Renal Advantage and Liberty Dialysis Deal Completed 2Renal Advantage and Liberty Dialysis Deal Completed 3
    (Date:5/25/2013)... 25, 2013 Studies from Johns Hopkins ... carrying excessive weight and their inability to get adequate ... losing weight can naturally relieve many symptoms. , ... in sleep quality was significantly associated with overall weight ... study dated November 6th, 2012, researchers monitored 77 ...
    (Date:5/25/2013)... Absolute Surgical Specialists, serving Sun City Center ... businesses throughout the country participating in Shop Local for a ... nationwide event as he understands what military families go through ... He said, “I wanted to give something back, as I ... live here too.” , Shop Local for a Cause has ...
    (Date:5/25/2013)... York, New York (PRWEB) May 25, 2013 ... who allegedly suffered serious, life-threatening episodes of internal bleeding while ... litigation underway in U.S. District Court, Southern District of Illinois, ... the Court’s website, 818 Pradaxa side effect claims had ... 2013. That’s up from 705 claims reported by the ...
    (Date:5/25/2013)... By working diligently for months on ... of the 2012 Lamborghini Aventador into their well-built fitments ... in the list of vehicles lined by SizeItUp for ... set to thrill automobile lovers in the year 2013. ... looks, the 2012 Lamborghini Aventador comes with extraordinarily spacious ...
    (Date:5/25/2013)... (PRWEB) May 25, 2013 According ... Emergency Management Market, 2013–2018", published by MarketsandMarkets is ... a CARC of 5.54% which analyzes and studies ... North America, Europe, Asia, and Rest of the ... Market Data Tables , 87 Figures ...
    Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4
    ... Garca Navarro, a researcher at the School of Pharmacy at ... colon and liver cancer. The new treatment has shown ... ,This discovery is the principal result of her doctoral ... Cancer Cells of the Colon, which was subsidized by the ...
    ... who suffer bouts of nausea and vomiting during their pregnancies ... but it seems that going through morning sickness is a ... who have conducted a new study and found that women ... risk of developing breast cancer later in life than expecting ...
    ... shown a decline, thanks to the comprehensive program in 2002, ... 2006 report shows a decline in the smoking rate ... past year, smoking decreased among men (from 22.5% to 19.9%) ... followed a year-long ad campaign aimed at prompting more smokers ...
    ... cause effects ranging from learning and memory capabilities to ... of St.Jude Childrens Research hospital . ... factora molecule that binds to a section of DNA near ... protein for which it codes. CREB activates genes in response ...
    ... who allegedly tried to get his 15-year-old son into the record ... said the accusation was a ploy by his detractors to defame ... a video recording of his son Dhileepan Raj, a tenth standard ... other doctors in the hope of making his son attain the ...
    ... occurs as a solid tumor in the abdomen, but ... the network of the body's sympathetic nervous system. ... neuroblastoma is a special case, accounting for 7 percent ... cancer deaths. ,Neuroblastoma is what physicians ...
    Cached Medicine News:Health News:Novel Treatment Beneficial for Colon and Liver Cancer 2Health News:Morning Sickness may Signify Lower Breast Cancer Risk 2Health News:Morning Sickness may Signify Lower Breast Cancer Risk 3Health News:New York Records Decline in Smoking Rate 2Health News:Research Studies on Molecular Switches of Gene 2Health News:The Bottleneck in Neuroblastoma 2
    ... BioControl multichannel has the ... the single channel model.The ... all seven multichannel and ... cone modules. Both pipettes ...
    ... in a wide variety of applications. • Whole ... can be freely rotated against the handle to ... an optimum angle towards the microtiter plate. • ... of most common pipette tips, and provides a ...
    ... value!, Comfortable feel and less hand ... Finer control while pipetting with smooth, light ... with long, lever tip ejector , Completely ... the need for recalibration , Easy-to-read precision ...
    ... Designed with 96-well plates in ... useful for molecular biology applications: PCR* ... 96-well plates, etc. Used with Diamond ... system, this product will maximize performance ...
    Medicine Products: